As Curia expands, it will add API site in upstate New York; In battle against food allergies, Alladapt to build site to prep for PhIII trials
In July, contract manufacturer AMRI rebranded as Curia, and wrangled two biotechs to aid in its move toward global expansion. Thursday, the company announced that it will up its commercial manufacturing at its Rensselaer, NY site.
Curia will invest more than $35 million to double the batch-size scaling and packaging operations, and allow Curia to manufacture APIs for new products.
“Our Rensselaer team’s history of excellence in delivering U.S.-based complex manufacturing solutions that enable our customers to provide vital treatments to patients is resulting in increasing demand,” CEO John Ratliff said in a press release. “Some of the life-saving products produced at Rensselaer are highly complex, including critical oncology therapeutics and novel treatments addressing unmet medical needs. The engineering and technology advances we have designed for the site will enhance our flexibility, efficiency and scale, allowing us to meet our customers’ current and future complex manufacturing needs.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.